$VRDN（Viridian Therapeutics） 5.2.1 快照：现价24.27｜市值2.75B｜52周区间13.18到34.29｜现金及等价物212.4M｜短期投资662.3M｜流动性合计874.7M｜季度经营现金流出105.3M｜跑道8.3个季度约2.1年｜年度收入70.8M｜净利润-342.6M｜研发338.9M｜资本支出-0.5M｜季度收入0.3M｜季度净利润-127.1M｜流动比率1264.9%｜毛利率100.0%｜营业利润率-512.91%｜技术选股A组分数78、硬条件命中、获利盘95.52%、套牢盘4.48%、90%集中度20.16（来源Nasdaq财报接口与技术选股 10/29/2026） 5.2.2 主营业务与产品技术亮点：专注甲状腺眼病等自身免疫罕见病抗体药物开发，属生物医药创新大类创新药基因子行业；核心管线为长效IGF-1R抗体，走皮下注射路线以替代静脉给药；管线形态为单一适应症深耕加多适应症拓展；客户与产业链位置为自研自产、面向专科内分泌与眼科渠道（业务描述，无数字） 5.2.3 事件促发点：FDA批准Lumvoa后估值重估讨论，已发生2026-10-28，量级中等，利多（来源Google News Simply Wall St 10/28/2026）；财报日未在数据块未来5日日历中列出，暂无已公开促发点 5.2.4 大行研报与消息汇总：Nasdaq分析师库买入12家持有0家卖出0家，目标价均值34.11、区间22.0到41.0，距现价约40.5%（来源Nasdaq分析师库 10/29/2026）；消息面Simply Wall St称FDA批准Lumvoa后估值仍偏低（来源Google News 10/28/2026）；头部机构专项目标价本次未采集 5.2.5 关键价位、触发与失效：日线支撑筹码峰22.0距现价10.32%｜日线压力20日高24.42距现价0.62%｜周线支撑周线MA10 21.46距现价11.58%｜周线压力52周高34.29距现价41.29%（来源个股筹码四元组 10/29/2026）；触发为放量站稳24.42；失效为跌破22.0；资金共振同向2项 5.2.6 情景：牛档34.29（周线压力52周高，从现价空间41.29%）；基准档24.42（日线压力20日高）；熊档21.46（周线支撑周线MA10） 5.2.7 结论：可买，1到2周期望先看24.42再看34.29，赔率约1比2以上，建议半仓，最大风险为临床与商业化节奏不及预期。

St. Louis rapper Sexyy Red just recreated Beyoncé’s iconic “Dangerously in Love” album cover, beaded top and all. But she added one big twist to the look, and the new music she dropped with it makes it very clear what she’s calling herself now.

St. Patrick's Catholic church sings the Arizona Cardinals 'fight song' at mass after each victory, with the church explaining: "A great tool to have; both youth and adults saying after every Cardinals win they are going to sing it at mass. They are thinking of our Mass, the gathering of people, and the celebration of the Eucharist. Some years we hardly sing it and other years they win so often that it becomes our gathering song. GoCardinals!"

St. Croix National Scenic Riverway winds through some of the Upper Midwest’s most scenic and least developed landscapes. Paddle beneath wooded bluffs, camp amid the Northwoods or cast a line surrounded by fall color. Photo by Craig Blacklock